MX2022000598A - Preparacion de compuestos antibacterianos. - Google Patents

Preparacion de compuestos antibacterianos.

Info

Publication number
MX2022000598A
MX2022000598A MX2022000598A MX2022000598A MX2022000598A MX 2022000598 A MX2022000598 A MX 2022000598A MX 2022000598 A MX2022000598 A MX 2022000598A MX 2022000598 A MX2022000598 A MX 2022000598A MX 2022000598 A MX2022000598 A MX 2022000598A
Authority
MX
Mexico
Prior art keywords
ridinilazole
preparation
crystalline forms
processes
bibenzo
Prior art date
Application number
MX2022000598A
Other languages
English (en)
Inventor
Francis Xavier Wilson
Jean-Francois Carniaux
Nigel Adams
Original Assignee
Summit Oxford Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GBGB1910250.8A external-priority patent/GB201910250D0/en
Priority claimed from GBGB1912144.1A external-priority patent/GB201912144D0/en
Application filed by Summit Oxford Ltd filed Critical Summit Oxford Ltd
Publication of MX2022000598A publication Critical patent/MX2022000598A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/444—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring heteroatom, e.g. amrinone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/13—Crystalline forms, e.g. polymorphs
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Oncology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Communicable Diseases (AREA)
  • Epidemiology (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

Se describen los procesos para la preparación de 2,2'-di(piridin-4-il)-1H,1'H-5,5'-bibenzo[d]imidazol (que además se puede conocer como 5,5'bis-[2-(4-piridinil)-1H-bencimidazol]), al que se hace referencia en la presente descripción con el nombre INN ridinilazol y derivados, sales, hidratos, solvatos, complejos, bioisósteros, metabolitos o profármacos farmacéuticamente aceptables de este. La invención se refiere además a diversas composiciones de ridinilazol purificado, a diversas formas cristalinas de ridinilazol, a procesos para su preparación y a preparaciones farmacéuticas relacionadas y usos de estas (que incluyen su uso médico y su uso en la síntesis efectiva a gran escala de ridinilazol).
MX2022000598A 2019-07-17 2020-07-16 Preparacion de compuestos antibacterianos. MX2022000598A (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
GBGB1910250.8A GB201910250D0 (en) 2019-07-17 2019-07-17 Preparation of antibacterial compounds
GBGB1912144.1A GB201912144D0 (en) 2019-08-23 2019-08-23 Antibacterial compounds
PCT/GB2020/051710 WO2021009514A1 (en) 2019-07-17 2020-07-16 Process for the preparation of ridinilazole and crystalline forms thereof

Publications (1)

Publication Number Publication Date
MX2022000598A true MX2022000598A (es) 2022-03-04

Family

ID=72148169

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2022000598A MX2022000598A (es) 2019-07-17 2020-07-16 Preparacion de compuestos antibacterianos.

Country Status (12)

Country Link
US (1) US20220289705A1 (es)
EP (1) EP3999502A1 (es)
JP (1) JP2022542822A (es)
KR (1) KR20220024617A (es)
CN (1) CN114127056A (es)
AU (1) AU2020315188A1 (es)
BR (1) BR112022000484A2 (es)
CA (1) CA3146788C (es)
IL (1) IL289453A (es)
MX (1) MX2022000598A (es)
WO (1) WO2021009514A1 (es)
ZA (1) ZA202200660B (es)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB202100471D0 (en) * 2021-01-14 2021-03-03 Summit Oxford Ltd Preparation of antibacterial compounds
WO2023213878A1 (en) * 2022-05-04 2023-11-09 Summit (Oxford) Limited Solid tablet dosage form of ridinilazole

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0793654A1 (de) 1994-11-17 1997-09-10 F. Hoffmann-La Roche Ag Antibakterielle dibenzimidazol-derivate
HUP0303494A3 (en) 2000-12-15 2009-08-28 Vertex Pharma Parmaceutical compositions containing bacterial gyrase inhibitors and uses thereof
KR101052433B1 (ko) 2002-06-13 2011-07-29 버텍스 파마슈티칼스 인코포레이티드 자이라제 및/또는 토포이소머라제 ⅳ 억제제로서의 2-우레이도-6-헤테로아릴-3ｈ-벤조이미다졸-4-카복실산 유도체 및 이를 포함하는 세균 감염 치료용 약제학적 조성물
CA2504448C (en) 2002-11-01 2012-06-19 Paratek Pharmaceuticals, Inc. Transcription factor modulating compounds and methods of use thereof
CA2562763A1 (en) 2004-04-23 2006-07-20 Paratek Pharmaceuticals, Inc. Transcription factor modulating compounds and methods of use thereof
EP1945209B1 (en) 2005-08-12 2018-05-30 United States Government As Represented By The Secretary of The United States Army And The U.S. Army Medical Research & Materiel Command Broad spectrum antibacterial compounds
EP1948635A1 (en) 2005-11-07 2008-07-30 Vertex Pharmaceuticals Incorporated Benzimidazole derivatives as gyrase inhibitors
GB0612428D0 (en) 2006-06-22 2006-08-02 Prolysis Ltd Antibacterial agents
GB0821913D0 (en) * 2008-12-02 2009-01-07 Price & Co Antibacterial compounds
WO2011151620A1 (en) * 2010-06-01 2011-12-08 Summit Corporation Plc Compounds for the treatment of clostridium difficile associated disease
WO2011151621A1 (en) 2010-06-01 2011-12-08 Summit Corporation Plc Compounds for the treatment of clostridium difficile associated disease
WO2011151618A2 (en) * 2010-06-01 2011-12-08 Summit Corporation Plc Compounds for the treatment of clostridium difficile-associated disease
HUE046150T2 (hu) * 2014-04-22 2020-02-28 Arqule Inc Helyettesített imidazopiridinil-amino-piridin vegyületek sói és polimorf formái
EP3692030B1 (en) 2017-10-05 2023-04-19 Sandoz AG Process for the preparation of ridinilazole using acid addition salts

Also Published As

Publication number Publication date
IL289453A (en) 2022-02-01
AU2020315188A1 (en) 2022-02-10
WO2021009514A1 (en) 2021-01-21
JP2022542822A (ja) 2022-10-07
CA3146788A1 (en) 2021-01-21
ZA202200660B (en) 2024-06-26
CN114127056A (zh) 2022-03-01
CA3146788C (en) 2024-06-18
EP3999502A1 (en) 2022-05-25
BR112022000484A2 (pt) 2022-03-08
US20220289705A1 (en) 2022-09-15
KR20220024617A (ko) 2022-03-03

Similar Documents

Publication Publication Date Title
CR20220230A (es) Inhibidores de pequeñas moléculas de mutante g12c de kras
MX2022006475A (es) Compuestos triciclicos sustituidos.
ZA202200660B (en) Process for the preparation of ridinilazole and crystalline forms thereof
MX2010007375A (es) Nuevos derivados de lupano.
YU30702A (sh) Novi derivati benzoimidazola, korisni agensi protiv proliferacije
BRPI0313942B8 (pt) derivados de benzimidazol úteis como agentes antiproliferativos, seus processos de preparação, composição farmacêutica compreendendo os mesmos e usos dos referidos compostos nas preparações de composições farmacêuticas
MX2021004000A (es) Derivados de piperidina.
MX2010003868A (es) Cis-imidazolinas quirales.
MX2010007374A (es) Nuevos derivados de c-21-ceto lupano, preparacion y uso de los mismos.
MX2021006544A (es) Inhibidores de cinasa dependiente de ciclina 9 (cdk9) y polimorfos de los mismos para uso como agentes para el tratamiento de cancer.
MX2014005075A (es) Formulaciones de sal de meglumina del acido 1-(5,6-dicloro-1h-benz o[d]imidazol-2-il)-1h-pirazol-4-carboxilico.
MX2022004451A (es) Heteroaril-bifenil-amidas para el tratamiento de enfermedades relacionadas con el ligando pd-l1.
MX2022004450A (es) Aminas de heteroaril-bifenilo para el tratamiento de enfermedades pd-l1.
MX2010013310A (es) Derivados de heterociclil urea para el tratamiento de infecciones bacterianas.
JOP20220063A1 (ar) مشتقات بيريدازين-3(2h)-أون ملتحمة بأزول
MX2022001789A (es) Derivados de 2-hidroxicicloalcan-1-carbamoilo.
JO2749B1 (en) Indole-2-Wen derivatives bilaterally substituted at position 3, their preparation and therapeutic application
MX2021003739A (es) Derivados de quinolino-pirrolidin-2-ona como inhibidores del gen mutado de ataxia telangiectasia (atm) y el uso de los mismos en el tratamiento de tumores sólidos.
ZA202203107B (en) Azaindole carboxamide compounds for the treatment of mycobacterial infections
MX2023011715A (es) Compuestos de oxoisoindolina sustituidos con piridinilo.
MX2022009898A (es) Compuesto de dihidronaftiridinona y metodo de preparacion del mismo y uso medico del mismo.
CA3155875A1 (en) BIARYL COMPOUND SUBSTITUTED BY SULFO OR CORRESPONDING SALT, METHOD FOR PREPARATION AND USE
ZA202203108B (en) Indole carboxamide compounds and use thereof for the treatment of mycobacterial infections
MX2024003028A (es) Derivados de 6 aza quinolina y usos relacionados.
ZA202203106B (en) Thiazole carboxamide compounds and use thereof for the treatment of mycobacterial infections